The NHS announced its plan to provide the latest innovative treatments for patients, just days after it celebrated its 70th anniversary. Treatments are grouped into five levels of priority, with those that cost less and offer more clinical benefit for patients relative to the other treatments being considered classified as level one, and treatments with the lowest relative clinical benefit and highest cost placed in the lowest category (level five).
- Level 1:
- Teriparatide for osteoporosis in men
- Level 2:
- Anakinra and tocilizumab for adult onset stills disease
- Anakinra to treat periodic fevers and autoinflammatory diseases (all ages)
- Keraprosthesis for corneal blindness
- Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (adults)
- Susoctocog alfa for acquired haemophilia A
- Level 3:
- Bendamustine with rituximab for first line treatment of advanced indolent non-hodgkins lymphoma
- Bendamustine with rituximab for the treatment of relapsed mantle cell lymphoma
- Selective dorsal rhizotomy
- Lomitapide for homozygous familial hypercholesterolemia
- Total pancreatectomy with islet transplantation for chronic pancreatitis
- Level 4:
- Human coagulation factor X for hereditary factor X deficiency
- Selexipag for pulmonary arterial hypertension
- Level 5:
- Everolimus for refractory seizures associated with tuberous sclerosis complex
There is sufficient funding available in this round to approve treatments in levels one to three. The remaining three treatments can be considered in the next prioritisation round in November 2018 and if successful could be funded in the 2019/20 financial year.
See full details here.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.